INTRODUCTION
Hyperkalemia in extremely low birth-weight (ELBW) infants is common 1, 2 even in the absence of oliguria. 3, 4 In first few days after birth it may cause life-threatening cardiac arrythmias.
One of the treatments for hyperkalemia consists of administration of Sodium PolyStyrene, Sulfonate (SPS) via oral and/or rectal routes, which infrequently cause bezoar formation 5 . ELBW infants with this complication develop either perforation or intestinal obstruction with high likelihood of mortality and morbidity. 5, 6 We report a case of an ELBW infant with hyperkalemia who had extensive bezoar formation and obstruction after SPS therapy, who was successfully treated with serial water soluble contrast enema (WSCE) without adverse sequelae.
CASE REPORT
A male infant with estimated gestational age of 23 weeks and a birth weight of 532 g was the first of twins born to a 22-year-old black female. The infant was delivered vaginally and intubated at birth because of severe respiratory distress. He subsequently received two doses of surfactant. Investigation for infection was negative.
The infant developed hyperkalemia at 12 hours after birth with a serum potassium (K + ) concentration of 7.3 mEq/l. Treatment consisted of sodium bicarbonate infusion, insulin-glucose infusion, several insulin-glucose boluses (0.5 units/g of dextrose/ kg/dose), furosemide and SPS 1 g/kg/dose every 4 hours via rectal and oral routes (18 g/kg over 3 days). The serum potassium concentration ranged between 6.3 and 9.1 mEq/l over next 3 days. Cardiac rhythm and rate remained in normal range. In the first 4 days of life, the urine output remained in the range of 6.5 to 7ml/ kg/h. The serum K subsided to 5.5 mEq/l 3 days after birth. SPS and insulin-glucose infusion were thus discontinued.
The infant was treated for patent ductus arteriosus with two doses of indomethacin on 6 and 7th day of life. Infant was started on feeds on the 10th day of life. After 3 days the infant developed severe pulmonary hemorrhage with clinical deterioration, severe metabolic acidosis and systemic hypotension that required vasopressor support. On the same day, the infant was found to have abdominal distension and palpable firm to hard masses throughout the abdomen. Greenish aspirate from the nasogastric tube was noted. Abdominal radiographs showed paucity of bowel gas with radio-opaque densities throughout the bowel ( Figure 1 ). Subsequent radiographs showed distended loops of bowel in mid and lower abdomen. The infant had meconium stools once or twice per day until the 6th day of life, but did not have any after the 7th day of life. The infant remained NPO. Radio-opaque concretions persisted on all subsequent X-rays with little change.
On the 28th day of life, the infant was given normal saline enemas, which resulted in a small pellet of white, chalk-like, firm stool about 2 to 3 cm in size. The infant did not respond to further normal saline enemas. Radiographs demonstrated increased bowel distension proximal to the concretions.
Consultation was obtained from the Pediatric Surgery service. An operative procedure was deferred because of the small size and poor respiratory status of the baby. Instead, four serial WSCE were performed under fluoroscopy on the 53rd, 55th, 56th, and 57th days of life (Figure 2 ). For the first WSCE, Omnipaque (iohexol) 180 mgI/ml (Nycomed, Princeton, NJ -Amersham Health) with an osmolality of 408 mOsm/l was used. For the three enemas that followed, Cystoconray II (iothalamate meglumine 17.2%) (Mallinkrodt, St. Louis) with an osmolality of 400 mOsm/l. The first two enemas were administered by gravity; the final two enemas were administered by careful hand injection, all under fluoroscopic guidance. The infant passed meconium stools with SPS plugs, and the abdomen became decompressed over the next few days. No adverse effects occurred as a result of the enema therapy. Radiologically and clinically, the bowel pattern normalized by the end of the second month of life. The infant was extubated on the 55th day of life and was discharged home at about 4 months of age on full feeds.
DISCUSSION
SPS is a benzene diethyl-polymer with ethenyl-benzene, sulfonated sodium salt, 7 which when retained in the colon releases sodium and absorbs potassium ions and a small amount of calcium and magnesium, thus lowering serum K, calcium and magnesium levels, sometimes increasing serum Na levels.
Hyperkalemia in VLBW infants in the absence of oliguria is because of transcellular efflux potassium ions from the cells to extracellular fluid, negative nitrogen balance and limited excretory capacity of the renal tubules to secrete potassium ions. 4 SPS is known to cause upper gastrointestinal injury in the form of hemorrhagic gastritis, erosion and ulceration, 9 it can also cause necrosis of small intestine and colo-rectal area causing ulceration, hematochezia and perforation in uremic patients. [8] [9] [10] In neonates, it was reported to cause constipation, cecal impaction, obstruction, abscess formation, hematochezia and perforation. 5, 6, 11 In 1981, Sherman et al. 12 reported that rectal and oral SPS administration could cause bowel opacification on abdominal radiographs. The binding of the SPS to intraluminal calcium may result in Figure 1 . AP supine abdominal radiographs on day 18. Increased abdominal girth, numerous concretions throughout the bowel and little bowel gas. Nasogastric tube in stomach and UAC catheter at L4. 
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Successful Treatment of Sodium PolyStyrene Sulfonate Bezoars radiographic density. 6 The predisposing factor for impaction in the present case is thought to be immature bowel hypomotility, perhaps complicated by functional ileus in this critically ill ELBW infant.
Serial WSCE may be performed as long as there is progressive clinical improvement following each therapeutic enema. The therapeutic rationale is similar to the use of WSCE in meconium plug syndrome or meconium ileus. The colon is opacified with water-soluble contrast in a retrograde manner and reflux obtained through the ileocecal valve in order to surround the filling defects with the hypertonic contrast agent. In our case, the bezoars were located in the distal small bowel by this time as the colon was free of filling defects. A slightly hyperosmolar agent (400 to 408 mOsm/ l) was used to draw water into the bowel lumen, helping to solubulize the pellets of SPS and move them distally into the colon. There is also a mechanical effect of distension of the unused colon by the enema itself that increases colon caliber and ideally is followed by actual passage of the SPS pellets and stools, reinforcing this cycle.
This procedure carries a potential risk of electrolyte imbalance, although not nearly so as much as with Gastrograffin TM and other more hypertonic agents. There is also a risk of perforation. In our case, the infant was a poor surgical candidate and at very high risk for complications.
We agree with the previous authors that SPS should not be used in critically ill infants unless it is an absolute necessity, since it is associated with significant complications including obstructing bezoars. Conservative management of intestinal obstruction with WSCE enemas would seem to be the initial treatment of choice, especially for ELBW infants.
